Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : World Heart Corp - WHRT and TSE/WHT -- Ignore unavailable to you. Want to Upgrade?

To: Dan Hamilton who wrote (239)	3/11/1999 12:20:00 PM
From: Mindshare	Read Replies (1) \| Respond to of 500

All your points are valid. However, the features you listed all involve peripheral devices, not the pump. None of them are proprietary or patented and can be used by any manufacturer. Data acquisition and power transmission techniques will evolve. These things can be improved and refined in an electronics lab, and don't require the human body. I think the reason they are not using wireless technologies is that you can't beat a cable for reliability. The number one motto for new medical devices under testing is AVOID DEVICE FAILURES AT ALL COSTS. One failure can set the device back years with regulatory agencies. I think you will see improved peripherals once the pump is proven to work in a large number of patients. The key factors to consider when evaluating different systems all involve the the pump itself. Some of these are (listed in order of importance): 1) Blood Cell Damage 2) Blood Clot Formation 3) Device size. 4) Power requirements 5) Device complexity 6) Failure modes 7) Reliability and device life 8) Manufacturing costs If you really want to know if the HeartSaver has a competitive advantage, then these are the questions to ask. The old saying "Don't put the cart before the horse" directly applies to this field. Comments are welcome. I'm not an expert on the clinical side, so my views could be off the mark.

To: Dan Hamilton who wrote (239)	4/13/1999 10:07:00 PM
From: the Chief	Respond to of 500

World Heart Corp - World Heart files share offering World Heart Corp WHT Shares issued 12,284,860 1999-04-13 close $19.5 Tuesday Apr 13 1999 An anonymous director reports World Heart has filed a registration statement in the United States and a short form preliminary prospectus in Canada under the Canada/U.S. multijurisdictional disclosure system in connection with a primary offering of two million shares by the company, and a secondary offering of 300,000 shares by a selling shareholder. In addition, WorldHeart and the selling shareholder will grant to the underwriters options to purchase an additional 300,000 and 45,000 shares respectively to cover overallotments. The secondary offering of shares is being made by Michael C.J. Cowpland, a director of the company. After selling a maximum of 345,000 shares, Dr. Cowpland will continue to hold 1,207,833 shares of WorldHeart. Dr. Cowpland has agreed with the underwriters that he will not offer for sale any additional shares of the company for 12 months following completion of the secondary offering. WorldHeart intends to use the net proceeds of this offering for continuing research and development activities, product development and commercialization, including costs of clinical trials for its HeartSaverVAD system and related commercialization activities. The lead manager of the offering is Merrill Lynch Canada Inc. and the co-managers are ScotiaMcLeod Inc. and CIBC Wood Gundy Securities Inc. A registration statement relating to the shares has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The shares may not be sold nor may offers to buy the shares be accepted prior to the time the registration statement becomes effective. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com